The news comes just over a year since the South African, state-owned nuclear medicine manufacturer resumed production, after a year of extended shutdowns that hurt its standing in the market for Mo-99 and those of other radiopharmaceuticals.
To read more please visit:
https://www.dotmed.com/news/story/49928
Source: HealthCare Business News